Abstract 2389: Role of Midkine in molecular targeted therapy to TIP1 for lung cancer treatment

Author(s):  
Vaishali Kapoor ◽  
Abhay K. Singh ◽  
Dinesh Thotala ◽  
Dennis Hallahan
Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2777
Author(s):  
Francesco Petrella

 [...]


BMJ Open ◽  
2015 ◽  
Vol 5 (12) ◽  
pp. e008587 ◽  
Author(s):  
Angela Mary Tod ◽  
Judy Redman ◽  
Ann McDonnell ◽  
Diana Borthwick ◽  
John White

Drugs ◽  
2011 ◽  
Vol 71 (17) ◽  
pp. 2231-2246 ◽  
Author(s):  
Laura Bonanno ◽  
Adolfo Favaretto ◽  
Massimo Rugge ◽  
Miquel Taron ◽  
Rafael Rosell

2006 ◽  
Vol 24 (11) ◽  
pp. 1761-1769 ◽  
Author(s):  
Ping Yang ◽  
Jon O. Ebbert ◽  
Zhifu Sun ◽  
Richard M. Weinshilboum

Inherent and acquired drug resistance is a cause of chemotherapy failure, and pharmacogenomic studies have begun to define gene variations responsible for varied drug metabolism, which influences drug efficacy. Platinum-based compounds are the most commonly used chemotherapeutic agents in the treatment of advanced stage lung cancer patients, and the glutathione metabolic pathway is directly involved in the detoxification or inactivation of platinum drugs. Consequently, genotypes corresponding to higher drug inactivation enzyme activity may predict poor treatment outcome. Available evidence is consistent with this hypothesis, although a definitive role for glutathione system genes in lung cancer prognosis needs to be elucidated. We present evidence supporting a role of the glutathione system in acquired and inherited drug resistance and/or adverse effects through the impact of either drug detoxification or drug inactivation, thus adversely effecting lung cancer treatment outcome. The potential application of glutathione system polymorphic genetic markers in identifying patients who may respond favorably, selecting effective antitumor drugs, and balancing drug efficacy and toxicity are discussed.


2021 ◽  
Vol 8 ◽  
Author(s):  
Vianey Rodriguez-Lara ◽  
Maria Rosa Avila-Costa

Lung cancer incidence and mortality have significantly increased in women worldwide. Lung adenocarcinoma is the most common form of lung cancer globally. This type of lung cancer shows differences by sex, including the mutational burden, behavior, clinical characteristics, and response to treatment. The effect of sex on lung cancer patients' survival is still controversial; however, lung adenocarcinoma is considered a different disease in women and men. Moreover, lung adenocarcinoma is strongly influenced by estrogen and is also different depending on the hormonal status of the patient. Young pre-menopausal women have been explored as an independent group. They presented in more advanced stages at diagnosis, exhibited more aggressive tumors, and showed poor survival compared to men and post-menopausal women, supporting the role of sex hormones in this pathology. Several reports indicate the estrogen's role in lung carcinogenesis and tumor progression. Thus, there are currently some clinical trials testing the efficacy of antihormonal therapy in lung cancer treatment. This mini review shows the updated data about lung cancer in women, its characteristics, the etiological factors that influence carcinogenesis, and the critical role of estrogen in lung cancer and treatment.


2004 ◽  
Vol 10 (12) ◽  
pp. 4233s-4237s ◽  
Author(s):  
Giuseppe Giaccone

Sign in / Sign up

Export Citation Format

Share Document